Latest News

December 15, 2022

Study E1910 consolidates the role of blinatumomab in acute lymphoblastic leukemia (ALL)

December 14, 2022

Blinatumomab further improves survival among patients with B-ALL and a good prognosis (study E1910)

December 13, 2022

Immunotherapy Plus Consolidation Chemo Improves Survival in B Lineage ALL

December 13, 2022

HealthDay News informs the public of the 12-year TAILORx results

December 13, 2022

Blinatumomab regimen may lead to ‘diminishing use of transplant’ for B-ALL subgroup (study E1910)

December 13, 2022

Press Release: Practice-changing trial results for acute lymphoblastic leukemia (ALL)

December 11, 2022

Press Release: A unique clinical trial leads to a dramatic decrease in early deaths from the rare and aggressive—yet highly curable—acute promyelocytic leukemia (APL)

December 6, 2022

Press Release: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes

October 28, 2022

Press Release: NCI Director Monica Bertagnolli delivers her first public speech at the ECOG-ACRIN Cancer Research Group meeting


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
43

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group